MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.18
+1.57
+4.07%
After Hours: 40.50 +0.32 +0.80% 17:47 09/25 EDT
OPEN
38.73
PREV CLOSE
38.61
HIGH
40.51
LOW
38.65
VOLUME
822.03K
TURNOVER
--
52 WEEK HIGH
58.72
52 WEEK LOW
30.02
MARKET CAP
6.38B
P/E (TTM)
-27.3967
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 09/07 21:15
Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?
Zacks · 09/04 15:31
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:
Business Wire · 09/02 14:00
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for leading research and development activities at ACADIA and will serve as a member of the company’s Executive
Business Wire · 08/31 13:00
5 Biotech Stocks That Could Be Worth a Look
Newly-hired analyst Danielle Brill launched coverage at Raymond James this week with a 490-page survey of her favorite biotech stocks. These are her favorites.
Barrons.com · 08/27 03:44
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. The lead development
Business Wire · 08/25 14:00
Acadia Pharma scoops up CerSci Therapeutics for $52.5M
Seeking Alpha - Article · 08/25 13:50
ACADIA Pharmaceuticals Acquires CerSci Therapeutics For $52.5M, Adds Novel Pain Program to Portfolio
- First-in-class, non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first half of 2021 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the acquisition of CerSci Therapeutics,
First-in-class, non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first half of 2021 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the acquisition of CerSci Therapeutics, · 08/25 13:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACAD. Analyze the recent business situations of ACADIA Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACAD stock price target is 59.22 with a high estimate of 71.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 403
Institutional Holdings: 165.01M
% Owned: 103.87%
Shares Outstanding: 158.86M
TypeInstitutionsShares
Increased
79
9.98M
New
105
1.54M
Decreased
94
13.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Stephen Biggar
President
Srdjan Stankovic
Chief Executive Officer/Director
Stephen Davis
Chief Financial Officer/Executive Vice President
Elena Ridloff
Executive Vice President/General Counsel/Secretary
Austin Kim
Executive Vice President
Gudarz Davar
Executive Vice President
Michael Yang
Senior Vice President
Stephanie Fagan
Senior Vice President
Mark Schneyer
Vice President/IR Contact Officer
Mark Johnson
Senior Vice President
Ponni Subbiah
Chief Accounting Officer
James Kihara
Independent Director
Julian Baker
Independent Director
Laura Brege
Independent Director
James Daly
Independent Director
Edmund Harrigan
Independent Director
Daniel Soland
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACAD
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.